NSTM
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
XVIPF
Price
$42.00
Change
-$0.00 (-0.00%)
Updated
Nov 1 closing price
Ad is loading...

NSTM vs XVIPF

Header iconNSTM vs XVIPF Comparison
Open Charts NSTM vs XVIPFBanner chart's image
NovelStem International
Price$0.01
Change-$0.00 (-0.00%)
Volume$10.02K
CapitalizationN/A
Xvivo Perfusion AB
Price$42.00
Change-$0.00 (-0.00%)
Volume$200
CapitalizationN/A
View a ticker or compare two or three
NSTM vs XVIPF Comparison Chart
Loading...
VS
NSTM vs. XVIPF commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NSTM is a Hold and XVIPF is a Hold.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (NSTM: $0.01 vs. XVIPF: $42.00)
Brand notoriety: NSTM and XVIPF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NSTM: 208% vs. XVIPF: 177%
Market capitalization -- NSTM: $10.63M vs. XVIPF: $905.23M
NSTM [@Medical Specialties] is valued at $10.63M. XVIPF’s [@Medical Specialties] market capitalization is $905.23M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NSTM’s FA Score shows that 0 FA rating(s) are green whileXVIPF’s FA Score has 0 green FA rating(s).

  • NSTM’s FA Score: 0 green, 5 red.
  • XVIPF’s FA Score: 0 green, 5 red.
According to our system of comparison, XVIPF is a better buy in the long-term than NSTM.

Price Growth

NSTM (@Medical Specialties) experienced а -69.75% price change this week, while XVIPF (@Medical Specialties) price change was -2.80% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.64%. For the same industry, the average monthly price growth was -0.19%, and the average quarterly price growth was -1.08%.

Reported Earning Dates

NSTM is expected to report earnings on Nov 04, 2024.

Industries' Descriptions

@Medical Specialties (+0.64% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
XVIPF($905M) has a higher market cap than NSTM($10.6M). XVIPF YTD gains are higher at: 84.211 vs. NSTM (-80.763). XVIPF has higher annual earnings (EBITDA): 29.2M vs. NSTM (-758.27K). XVIPF has more cash in the bank: 171M vs. NSTM (40.6K). NSTM has less debt than XVIPF: NSTM (358K) vs XVIPF (27.6M). XVIPF has higher revenues than NSTM: XVIPF (524M) vs NSTM (12K).
NSTMXVIPFNSTM / XVIPF
Capitalization10.6M905M1%
EBITDA-758.27K29.2M-3%
Gain YTD-80.76384.211-96%
P/E RatioN/A344.83-
Revenue12K524M0%
Total Cash40.6K171M0%
Total Debt358K27.6M1%
FUNDAMENTALS RATINGS
NSTM vs XVIPF: Fundamental Ratings
NSTM
XVIPF
OUTLOOK RATING
1..100
9188
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
10048
SMR RATING
1..100
9768
PRICE GROWTH RATING
1..100
9846
P/E GROWTH RATING
1..100
10086
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NSTM's Valuation (51) in the null industry is somewhat better than the same rating for XVIPF (88). This means that NSTM’s stock grew somewhat faster than XVIPF’s over the last 12 months.

XVIPF's Profit vs Risk Rating (48) in the null industry is somewhat better than the same rating for NSTM (100). This means that XVIPF’s stock grew somewhat faster than NSTM’s over the last 12 months.

XVIPF's SMR Rating (68) in the null industry is in the same range as NSTM (97). This means that XVIPF’s stock grew similarly to NSTM’s over the last 12 months.

XVIPF's Price Growth Rating (46) in the null industry is somewhat better than the same rating for NSTM (98). This means that XVIPF’s stock grew somewhat faster than NSTM’s over the last 12 months.

XVIPF's P/E Growth Rating (86) in the null industry is in the same range as NSTM (100). This means that XVIPF’s stock grew similarly to NSTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MYIEX8.77N/A
N/A
MassMutual International Eq Svc
CCPAX14.20N/A
N/A
FS Chiron Capital Allocation A
ACGIX23.29-0.03
-0.13%
Invesco Growth and Income A
TEEFX71.99-0.15
-0.21%
T. Rowe Price Tax-Efficient Equity I
RGABX69.63-0.22
-0.31%
American Funds Growth Fund of Amer R2

NSTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, NSTM has been loosely correlated with SNN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NSTM jumps, then SNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NSTM
1D Price
Change %
NSTM100%
+19.80%
SNN - NSTM
43%
Loosely correlated
+0.16%
TFX - NSTM
39%
Loosely correlated
-1.84%
IDXX - NSTM
27%
Poorly correlated
-0.62%
TRXO - NSTM
27%
Poorly correlated
N/A
XVIPF - NSTM
22%
Poorly correlated
N/A
More

XVIPF and

Correlation & Price change

A.I.dvisor tells us that XVIPF and USAQ have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XVIPF and USAQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XVIPF
1D Price
Change %
XVIPF100%
N/A
USAQ - XVIPF
22%
Poorly correlated
N/A
NSTM - XVIPF
21%
Poorly correlated
+19.80%
VYCO - XVIPF
17%
Poorly correlated
N/A
ZTEK - XVIPF
9%
Poorly correlated
+16.16%
LUNG - XVIPF
6%
Poorly correlated
+13.56%
More